Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Cited by (1,034)

Items 601–700 of 1,034

1. Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses
   Jerry C. H. Tam, Abbie C. Sibayan, J. Seow, C. Graham, Ashwini Kurshan, B. Merrick, Richard J. Stanton, K. Doores · 2025 · bioRxiv
2. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine
   N. Petrovsky · 2024 · Human Vaccines & Immunotherapeutics
3. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug
   Qianyun Liu, Chenguang Cai, 黄燕燕, Li Zhou, Yanbin Guan, Shiying Fu, Youyou Lin, Ting Yang, Huan Yan, Zhen Zhang et al. · 2024 · Cell Death and Disease
4. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif
   Hang Su, Jun Zhang, Zhenfei Yi, Sajid Ullah Khan, Mian Peng, Liang Ye, Alan Bao, Han Zhang, Guangli Suo, Qian Li et al. · 2024 · hLife
5. Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection
   Ruoke Wang, Yang Han, Rui Zhang, Jiayi Zhu, Xuanyu Nan, Yaping Liu, Ziqing Yang, Bini Zhou, Jinfang Yu, Zichun Lin et al. · 2023 · Immunity
6. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge
   Yoshikazu Honda-Okubo, Lei Li, Greiciely Andre, King Ho Leong, E. Howerth, Anne-Gaelle Bebin-Blackwell, T. Ross, N. Petrovsky · 2023 · Vaccine
7. State of the Art in Epitope Mapping and Opportunities in COVID-19
   Samira M. Hamed, Masarra M. Sakr, Ghadir S. El-Housseiny, Reham Wasfi, Khaled M. Aboshanab · 2023 · Future Science OA
8. Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike—ACE2 Protein–Protein Interaction from a Chemical Space of Privileged Protein Binders
   Sung-Ting Chuang, Péter Buchwald · 2022 · Pharmaceuticals
9. Broadly neutralizing antibodies against Omicron variants of SARS-CoV-2 derived from mRNA-lipid nanoparticle-immunized mice
   Ruei‐Min Lu, Kang-Hao Liang, Hsiao-Ling Chiang, Fu‐Fei Hsu, Hsiu-Ting Lin, Wan-Yu Chen, Feng-Yi Ke, Monika Kumari, Yu‐Chi Chou, Mi‐Hua Tao et al. · 2023 · Heliyon
10. Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection
    C. Kaku, Alan J. Bergeron, C. Ahlm, J. Normark, M. Sakharkar, M. Forsell, L. Walker · 2022 · bioRxiv
11. Deep dissection of the antiviral immune profile of patients with COVID-19
    Djordje Atanackovic, Stephanie V. Avila, Forat Umair Lutfi, Diego de Miguel‐Pérez, Xiaoxuan Fan, Gabriela Sanchez‐Petitto, Erica R. Vander Mause, Jonathan Siglin, John W. Baddley, Heather Dorothy Mannuel et al. · 2021 · Communications Biology
12. Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago
    Min Qiang, Peixiang Ma, Yu Li, Hejun Liu, Adam C. Harding, Chenyu Min, Fulian Wang, Lili Liu, M. Yuan, Qun Ji et al. · 2021 · Advancement of science
13. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative
    Isaac Kyei-Barffour, Samuel Akwetey Addo, E. Aninagyei, George Ghartey-Kwansah, D. O. Acheampong · 2021 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
14. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity
    Adam S. Olia, Yaroslav Tsybovsky, Steven J. Chen, Cuiping Liu, Alexandra F. Nazzari, Li Ou, Lingshu Wang, Wing‐Pui Kong, Kwanyee Leung, Tracy W. B. Liu et al. · 2021 · Journal of Biological Chemistry
15. Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity
    Frauke Muecksch, H. Wise, K. Templeton, Becky Batchelor, M. Squires, Kirsty McCance, L. Jarvis, K. Malloy, E. Furrie, C. Richardson et al. · 2021 · medRxiv
16. Outpatient Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection to Prevent Coronavirus Disease 2019 Progression
    Myron S. Cohen, David Alain Wohl, William A. Fischer, Davey M. Smith, Joseph J. Eron · 2021 · Clinical Infectious Diseases
17. Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis
    P. Rai, Christina Chuong, T. LeRoith, James W. Smyth, Julia Panov, M. Levi, K. Kehn-Hall, Nisha K. Duggal, James Lucarelli · 2021 · bioRxiv
18. Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques
    T. Nomura, Hiroyuki Yamamoto, M. Nishizawa, T. Hau, S. Harada, Hiroshi Ishii, Sayuri Seki, Midori Nakamura-Hoshi, Midori Okazaki, Sachie Daigen et al. · 2021 · bioRxiv
19. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines
    Yan Guo, Wenhui He, H. Mou, Lizhou Zhang, Jing Chang, Shoujiao Peng, Amrita Ojha, Rubens Tavora, M. Parcells, G. Luo et al. · 2021 · mBio
20. Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrate the Functional Importance of the Receptor Binding Domain
    G. Mantus, Lindsay E. Nyhoff, Robert C Kauffman, V. Edara, Li-Lin Lai, K. Floyd, Pei-Yong Shi, V. Menachery, S. Edupuganti, E. Scherer et al. · 2021 · Journal of Immunology
21. Phylodynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment
    J. Cardona-Ospina, Diana M. Rojas-Gallardo, S. Garzón-Castaño, E. Jiménez-Posada, A. Rodriguez-Morales · 2021 · Human Vaccines & Immunotherapeutics
22. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
    KY Oguntuyo, C. Stevens, Chuan-Tien Hung, Satoshi Ikegame, Joshua A. Acklin, S. Kowdle, Jillian C. Carmichael, Hsin-Ping Chiu, Kristopher D. Azarm, Griffin D Haas et al. · 2021 · mBio
23. Modalities and Mechanisms of Treatment for Coronavirus Disease 2019
    Zhihong Zuo, Ting Wu, Liangyu Pan, Chenzhe Zuo, Yingchuo Hu, Xuan Luo, Liping Jiang, Zanxian Xia, Xiaojuan Xiao, Jing Liu et al. · 2021 · Frontiers in Pharmacology
24. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library
    Yu Jung Kim, Min-Ho Lee, Se-Ra Lee, Hyo-Young Chung, Kwangmin Kim, Tae Gyu Lee, Dae Young Kim · 2021 · International Journal of Molecular Sciences
25. A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2
    Xiaolei Cai, Aleksander Prominski, Yiliang Lin, Nicholas Ankenbruck, Jillian Rosenberg, Min Chen, Jiu-Yun Shi, E. Chang, Pablo Penaloza-MacMaster, Bo-Zhi Tian et al. · 2020 · bioRxiv
26. Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles
    Chen-Hua Fan, J. Keeffe, Kathryn E. Malecek, Alexander A. Cohen, A. West, Viren A. Baharani, Annie V. Rorick, Han Gao, Priyanthi N. P. Gnanapragasam, Semi Rho et al. · 2025 · bioRxiv
27. The DNA glycosylase NEIL2 is protective during SARS-CoV-2 infection
    N. Tapryal, Anirban Chakraborty, Kaushik Saha, Azharul Islam, L. Pan, K. Hosoki, I. Sayed, J. Duran, Joshua Alcantara, Vanessa Castillo et al. · 2023 · Nature Communications
28. Standardizing cassette-based deep mutagenesis by Golden Gate assembly
    Nicolas Daffern, I. Francino-Urdaniz, Z. Baumer, T. Whitehead · 2023 · Biotechnology and Bioengineering
29. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
    Siriruk Changrob, Peter Halfmann, Hejun Liu, Jonathan L. Torres, Joshua J.C. McGrath, Gabriel Ozorowski, Lei Li, G. Dewey Wilbanks, Makoto Kuroda, Tadashi Maemura et al. · 2023 · Journal of Clinical Investigation
30. Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID‐19 survivors
    Chen Jia, Zhi-Guo Zhou, Wenjing Pan, Pan Zhang, Ming Yang, Ming Zhao, Bo Li, Ping Liu, Qian-Qian Zhang, Xiang-long Kong et al. · 2022 · Journal of Medical Virology
31. De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV ‐2 spike receptor binding domain ( RBD )
    Veda Sheersh Boorla, Ratul Chowdhury, Ranjani Ramasubramanian, Brandon Ameglio, Rahel Frick, Jeffrey J. Gray, Costas D. Maranas · 2022 · Proteins Structure Function and Bioinformatics
32. Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
    Marianna Agudelo, Frauke Muecksch, Dennis J. Schaefer-Babajew, Alice Cho, Justin DaSilva, Eva Bednarski, Víctor Ramos, Thiago Y. Oliveira, Melissa Cipolla, Anna Gazumyan et al. · 2022 · The Journal of Experimental Medicine
33. Epitope mapping of neutralising anti‐SARS‐CoV‐2 monoclonal antibodies: Implications for immunotherapy and vaccine design
    Somayeh Ghotloo, Faezeh Maghsood, Forough Golsaz‐Shirazi, Mohammad Mehdi Amiri, Christiane Moog, Fazel Shokri · 2022 · Reviews in Medical Virology
34. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity
    Alona Kuzmina, Seraj Wattad, Stanislav Engel, Elli Rosenberg, Ran Taube · 2022 · Viruses
35. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
    Nicole V. Tolan, A. Sherman, Guo-Hai Zhou, K. Nabel, M. Desjardins, Stacy E. F. Melanson, S. Kanjilal, S. Moheed, John A Kupelian, R. Kaufman et al. · 2022 · Microbiology spectrum
36. Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain
    C. Patrick, V. Upadhyay, Alexandra Lucas, Krishna M. G. Mallela · 2022 · bioRxiv
37. Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction
    S. Rouhani, Jonathan A. Trujillo, A. Pyzer, Jovian Yu, Jessica L. Fessler, Alexandra Cabanov, Emily F. Higgs, Kyle R Cron, Y. Zha, Yihao Lu et al. · 2021 · medRxiv
38. Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies
    Shane Miersch, Nikhil Sharma, Reza Saberianfar, Chao Chen, F. Caccuri, Alberto Zani, A. Caruso, J. Case, Michael S. Diamond, G. Amarasinghe et al. · 2021 · bioRxiv
39. A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain
    Xinyue Chang, A. Zeltins, M. Mohsen, Zahra Gharailoo, L. Zha, Xue-Lan Liu, S. Walton, M. Vogel, M. Bachmann · 2021 · Vaccines
40. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika
    M. Abernathy, K. A. Dam, S. Esswein, C. A. Jette, P. Bjorkman · 2021 · Viruses
41. Genetically-engineered hamster models: applications and perspective in dyslipidemia and atherosclerosis-related cardiovascular disease
    George Liu, Pingping Lai, Jiabao Guo, Yu-Hui Wang, X. Xian · 2021 · Medical Review
42. Construction of a new chromosome-scale, long-read reference genome assembly for the Syrian hamster, Mesocricetus auratus
    R. Harris, M. Raveendran, Dustin T. Lyfoung, F. Sedlazeck, M. Mahmoud, T. Prall, J. Karl, H. Doddapaneni, Q. Meng, Yi Han et al. · 2021 · bioRxiv
43. Recent progress of surface plasmon resonance in the development of coronavirus disease-2019 drug candidates
    Qian Wang, Zhen-Ming Liu · 2021 · European Journal of Medicinal Chemistry Reports
44. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
    Robert H. Bortz, Catalina Florez, Ethan Laudermilch, Ariel S. Wirchnianski, Gorka Lasso, Ryan J. Malonis, George Ivanov Georgiev, Olivia Vergnolle, Natalia G. Herrera, Nicholas C. Morano et al. · 2021 · mSphere
45. Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
    Beatriz Olea, Eliseo Albert, Ignacio Torres, Paula Amat, María José Remigia, Roberto Gozalbo‐Rovira, Jesús Rodríguez‐Díaz, Javier Buesa, María Luisa Blasco, Josep Redón et al. · 2021 · Journal of Clinical Virology
46. A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters
    Bao-Zhong Zhang, Xiaolei Wang, Shuo-Feng Yuan, Wenjun Li, Y. Dou, V. Poon, C. Chan, Jian-Piao Cai, K. Chik, K. Tang et al. · 2021 · Emerging Microbes and Infections
47. Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
    L. Grandjean, A. Saso, A. Torres, T. Lam, J. Hatcher, Rosie Thistlethwayte, M. Harris, Timothy Best, Marina Johnson, H. Wagstaffe et al. · 2020 · medRxiv
48. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes
    Steven C. Wall, Naveenchandra Suryadevara, Changil Kim, Andrea R. Shiakolas, Clinton M. Holt, Emma B Irbe, Perry T. Wasdin, Yukthi P. Suresh, E. Binshtein, Elaine C. Chen et al. · 2023 · Cell Reports Medicine
49. Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
    J. Seow, Z. A. Shalim, C. Graham, Simon Kimuda, Aswin Pillai, T. Lechmere, Ashwini Kurshan, Atika M. Khimji, L. Snell, G. Nebbia et al. · 2023 · mBio
50. SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters
    Jessica Plunkard, Kathleen R. Mulka, Rui-Feng Zhou, P. Tarwater, William Zhong, M. Lowman, Amanda Wong, A. Pekosz, J. Villano · 2023 · mBio
51. Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations
    Gabrielle Gimenes Lima, A. Portilho, E. D. De Gaspari · 2022 · Pathogens
52. Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge
    Ram Nechooshtan, Sharon Ehrlich, M. Vitikainen, A. Makovitzki, Eyal Dor, Hadar Marcus, Idan Hefetz, Shani Pitel, M. Wiebe, Anne Huuskonen et al. · 2022 · Vaccines
53. Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
    Laura Radić, Kwinten Sliepen, Victor C. Yin, Mitch Brinkkemper, Joan Capella-Pujol, Angela I. Schriek, Jonathan L. Torres, Sandhya Bangaru, Judith A. Burger, Meliawati Poniman et al. · 2023 · iScience
54. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses
    H. Lim, B.-H. Kok, C. Lim, A. A. Abdul Majeed, C. Leow, C. Leow · 2022 · Biomedical Engineering Advances
55. Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development
    P. Weidenbacher, Sriharshita Musunuri, Abigail E. Powell, Shao-Geng Tang, J. Do, M. Sanyal, Peter S. Kim · 2022 · Biochemistry
56. Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
    Edwards Pradenas, Maria Ubals, V. Urrea, C. Suñer, B. Trinité, E. Riveira-Muñoz, S. Marfil, C. Ávila-Nieto, M. L. Rodríguez de la Concepción, F. Tarrés-Freixas et al. · 2022 · Frontiers in Immunology
57. Breakthrough SARS-CoV-2 infections after vaccination: a critical review
    Zainab Mohseni Afshar, M. Barary, R. Hosseinzadeh, Amirmasoud Alijanpour, Dariush Hosseinzadeh, S. Ebrahimpour, Kosar Nazary, Terence T. Sio, M. Sullman, Kristin V. Carson-Chahhoud et al. · 2022 · Human Vaccines & Immunotherapeutics
58. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
    Dongyan Zhou, Run-Hong Zhou, Zhi-Wei Chen · 2021 · Immunotherapy Advances
59. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
    B. Vanhove, S. Marot, Ray T. Y. So, B. Gaborit, G. Evanno, I. Malet, Guillaume Lafrogne, Edwige Mevel, C. Ciron, Pierre-Joseph Royer et al. · 2021 · Frontiers in Immunology
60. No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
    Meryem Seda Ercanoglu, Lutz Gieselmann, Sabrina Dähling, Nareshkumar Poopalasingam, Susanne Detmer, Manuel Koch, Michael Korenkov, Sandro Halwe, Michael Klüver, Veronica Di Cristanziano et al. · 2022 · iScience
61. Detection and Neutralization of SARS-CoV-2 Using Non-conventional Variable Lymphocyte Receptor Antibodies of the Evolutionarily Distant Sea Lamprey
    Leslie Y. T. Leung, Srijit Khan, P. Budylowski, Zhi-Jie Li, S. Goroshko, Yanling Liu, Shilan Dong, J. Carlyle, J. Rini, M. Ostrowski et al. · 2021 · Frontiers in Immunology
62. Robust and low-cost ELISA based on IgG-Fc tagged recombinant proteins to screen for anti-SARS-CoV-2 antibodies
    É. Frumence, Grégorie Lebeau, Wildriss Viranaicken, A. Dobi, Damien Vagner, Mahary Lalarizo Rakoto, Anne-Laure Sandenon Seteyen, C. Giry, A. Septembre-Malaterre, L. Raffray et al. · 2021 · JIM - Journal of Immunological Methods
63. Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins
    Adam Leach, Ami Miller, Emma M. Bentley, Giada Mattiuzzo, Jemima C. Thomas, Craig McAndrew, Rob van Montfort, Terence Howard Rabbitts · 2021 · Scientific Reports
64. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies
    Meghan E. Garrett, Jared Galloway, Helen Y. Chu, Hannah L. Itell, Caitlin I. Stoddard, Caitlin R. Wolf, Jennifer K. Logue, Dylan McDonald, Haidyn Weight, Frederick A. Matsen IV et al. · 2021 · Cell
65. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
    Hyeseong Cho, K. K. Gonzales-Wartz, De-Li Huang, M. Yuan, M. Peterson, Janie Y. Liang, N. Beutler, J. Torres, Yu Cong, E. Postnikova et al. · 2021 · bioRxiv
66. Immunological and cardio-vascular pathologies associated with SARS-CoV-2 infection in golden syrian hamster
    Zaigham Abbas Rizvi, Rajdeep Dalal, Srikanth Sadhu, Yashwant Kumar, Tripti Srivastava, S. Gupta, Suruchi Agarwal, M. Tripathy, A. Yadav, G. Medigeshi et al. · 2021 · bioRxiv
67. Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motif
    Blake Marie Hauser, Maya Sangesland, Evan Christopher Lam, Kerri St. Denis, Jared E. Feldman, Ashraf Siddig Yousif, Timothy M. Caradonna, Ty Kannegieter, Alejandro Benjamin Balazs, Daniel Lingwood et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
68. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19
    Junsen Chen, Rui Huang, Yiwen Nie, Xinyue Wen, Ying Wu · 2020 · Virologica Sinica
69. Systemic and Mucosal Antibody Responses to SARS-CoV-2 Variant-Specific Prime-and-Boost and Prime-and-Spike Vaccination: A Comparison of Intramuscular and Intranasal Bivalent Vaccine Administration in a Murine Model
    Mariam Maltseva, Yannick Galipeau, Pauline S. McCluskie, Nicolas Castonguay, C. Cooper, Marc-André Langlois · 2025 · Vaccines
70. Preclinical animal models to evaluate therapeutic antiviral antibodies.
    Amse De Meyer, P. Meuleman · 2024 · Antiviral Research
71. Perspectives on SARS-CoV-2 Cases in Zoological Institutions
    Remco A. Nederlof, M. A. de la Garza, J. Bakker · 2024 · Veterinary Sciences
72. Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
    M. Lebedin, C. Ratswohl, A. Garg, Marta Schips, Clara Vázquez García, Lisa Spatt, C. Thibeault, B. Obermayer, J. Weiner, I. M. Velásquez et al. · 2024 · iScience
73. SARS-CoV-2 specific sIgA in saliva increases after disease-related video stimulation
    Judith K. Keller, A. Dulovic, Jens Gruber, Johanna Griesbaum, N. Schneiderhan-Marra, Clemens Wülfing, Jana Kruse, A. Hartmann, Esther K Diekhof · 2023 · Scientific Reports
74. Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines
    Yixiang Deng, C. Atyeo, D. Yuan, T. Chicz, T. Tibbitts, M. Gorman, Sabian Taylor, V. Lecouturier, D. Lauffenburger, R. Chicz et al. · 2023 · Cell Reports
75. Activated interstitial macrophages are a predominant target of viral takeover and focus of inflammation in COVID-19 initiation in human lung
    T. Wu, K. Travaglini, Arjun Rustagi, Duo Xu, Yue Zhang, Leonid Andronov, SoRi Jang, A. Gillich, Roozbeh Dehghannasiri, Giovanny J. Martínez-Colón et al. · 2023 · bioRxiv
76. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models
    Qiuxue Han, Shen Wang, Zhenshan Wang, Cheng Zhang, Xinyue Wang, Na Feng, Tiecheng Wang, Yongkun Zhao, Hang Chi, Feihu Yan et al. · 2023 · Virologica Sinica
77. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
    G. N. Llewellyn, Hsu-Yu Chen, G. Rogers, Xiaoli Huang, Philipp Sell, Jill E. Henley, P. Cannon · 2023 · bioRxiv
78. Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants
    Arasu Balasubramaniyam, E. Ryan, Dallas R. Brown, Therwa Hamza, William Harrison, M. Gan, R. Sankhala, Wei-Hung Chen, E. Martinez, J. Jensen et al. · 2022 · Vaccines
79. A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor
    Miao Wang, Qing Fan, Bing Zhou, Haocheng Ye, Senlin Shen, Jiazhen Yu, Lin Cheng, Xiangyang Ge, Bin Ju, Zheng Zhang · 2022 · Cell Reports
80. COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
    Saptarshi Sinha, Vanessa Castillo, Celia R. Espinoza, Courtney Tindle, Ayden G. Fonseca, Jennifer M. Dan, Gajanan Dattatray Katkar, Soumita Das, Debashis Sahoo, Pradipta Ghosh · 2022 · EBioMedicine
81. Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies
    D. Beshnova, Yan Fang, Mingjian Du, Yehui Sun, Feng-He Du, Jianfeng Ye, Zhi-Jian J. Chen, Bo Li · 2022 · Computational and Structural Biotechnology Journal
82. Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
    Shengtao Fan, Kang Xiao, Dandan Li, Heng Zhao, Jingjing Zhang, Li Yu, Penglan Chang, Shuangli Zhu, Xingli Xu, Yun Liao et al. · 2021 · Emerging Microbes & Infections
83. Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage
    Green Kim, D. H. Kim, H. Oh, Seongman Bae, Ji-Soo Kwon, Min-Jae Kim, Eunyoung Lee, Eun-Ha Hwang, Hoyin Jung, Bon-Sang Koo et al. · 2021 · Journal of Infectious Diseases
84. Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers.
    K. Saker, V. Escuret, Virginie Pitiot, Amélie Massardier-Pilonchéry, Stéphane Paul, Bouchra Mokdad, Carole Langlois-Jacques, Muriel Rabilloud, David Goncalves, N. Fabien et al. · 2021 · medRxiv
85. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
    Guidenn Sulbarán, Pauline Maisonnasse, Axelle Amen, Grégory Effantin, Delphine Guilligay, Nathalie Dereuddre‐Bosquet, Judith A. Burger, Meliawati Poniman, Marloes Grobben, Marlyse Buisson et al. · 2022 · Cell Reports Medicine
86. An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19
    Seyed Mostafa Monzavi, Mahmood Naderi, Naser Ahmadbeigi, A.M. Kajbafzadeh, Samad Muhammadnejad · 2021 · Cellular Immunology
87. What we know and still ignore on COVID‐19 immune pathogenesis and a proposal based on the experience of allergic disorders
    E. Maggi, B. Azzarone, G. Canonica, L. Moretta · 2021 · Allergy. European Journal of Allergy and Clinical Immunology
88. Effects of common mutations in the SARS-CoV-2 Spike RBD domain and its ligand the human ACE2 receptor on binding affinity and kinetics
    Michael I. Barton, S. MacGowan, Mikhail A. Kutuzov, Omer Dushek, G. Barton, P. Anton van der Merwe · 2021 · bioRxiv
89. Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2
    Fred D. Mast, Peter C. Fridy, Natalia E. Ketaren, Junjie Wang, Erica Y. Jacobs, J. P. Olivier, Tanmoy Sanyal, K. Molloy, Fabian Schmidt, Magda Rutkowska et al. · 2021 · bioRxiv
90. Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy
    Xiao-Yi Zhu, Fei Yu, Yan-Ling Wu, T. Ying · 2021 · Antibody Therapeutics
91. Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits
    A. Banerjee, Upasana Ganguly, S. Saha, S. Chakrabarti, R. Saini, R. Rawal, L. Saso, Sasanka Chakrabarti · 2021 · Expert Review of Anti-Infective Therapy
92. ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV
    S. Madhi, A. Koen, L. Fairlie, C. Cutland, V. Baillie, S. Padayachee, K. Dheda, S. Barnabas, Q. Bhorat, Carmen Briner et al. · 2021 · Research Square
93. Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing
    A. Komarov, A. Kaznadzey, Yue Li, M. Kireeva, I. Mazo · 2021 · Diagnostics
94. COVID-19 antibody development fueled by HIV-1 bNAb research
    Pilar Mendoza, Julio C. C. Lorenzi, C. Gaebler · 2020 · Current Opinion in HIV and AIDS
95. Immunogenicity of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
    V. Naranbhai, W. Garcia-Beltran, Cristhian Berrios Mairena, J. Thierauf, Christina C. Chang, Grace Kirkpatrick, M. Onozato, Ju Cheng, Kerri J. St. Denis, E. Lam et al. · 2021 · medRxiv
96. Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift
    Ge Song, Meng Yuan, Hejun Liu, Tazio Capozzola, Ryan N. Lin, Jonathan L. Torres, Wanting He, Rami Musharrafieh, Katharina Dueker, Pan-Pan Zhou et al. · 2025 · Cell Reports
97. A Structural Voyage Toward the Landscape of Humoral and Cellular Immune Escapes of SARS ‐ CoV ‐2
    Jun Liu, Yan Wu, George F. Gao · 2025 · Immunological Reviews
98. Importance of the Cysteine-Rich Domain of Snake Venom Prothrombin Activators: Insights Gained from Synthetic Neutralizing Antibodies
    Laetitia E. Misson Mindrebo, J. Mindrebo, Quoc Tran, Mark C. Wilkinson, Jessica M. Smith, Megan Verma, N. Casewell, G. Lander, J. Jardine · 2024 · Toxins
99. Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing
    Puja Jaishwal, Kisalay Jha, Satarudra Prakash Singh · 2024 · International Journal of Biological Macromolecules
100. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant
     Liuhai Zheng, Huifang Wang, Xueyan Liu, Chengchao Xu, Mingxiong Tian, Guangwei Shi, Chongzhi Bai, Zhijie Li, Jigang Wang, Shuwen Liu · 2024 · Journal of Medical Virology